PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Subsettine for Form 1449/PTO Complete if Known 10/531,540 **Application Number** April 15, 2005 Filing Date INFORMATION DISCLOSURE Stanka PERC First Named Inventor STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) **Examiner Name** Sheet of 2 Attorney Docket Number 4061-27PUS

			U.S. PATE	NT DOCUMENTS	Mary 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Examiner Initials*	Cite No. 1	Document Number  Number-Kind-Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-6,906,062	06/14/2005	Chhabada et al.	
		US-			
		US-			1
		US-			

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	T <sup>6</sup>				
		Country Code <sup>3-</sup> Number <sup>4-</sup> Kind-Code <sup>5 (if known</sup>			Relevant Figures Appear	_				
		WO 03/026610	04/03/2003	Ranbaxy Laboratories						
		EP 0830864 A1	03/25/1998	Eli Lilly & Co.						
		DE 69718731 T2	09/11/2003	Eli Lilly & Co.						
-		WO 99/61027	12/02/1999	Eli Lilly & Co.						

Examiner Signature	 Date Considered		

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO					Complete if Known		
					Application Number	10/531,540	
INEOI	RMATIO	NI INI	CCI O	CHIDE	Filing Date	April 15, 2005	
					First Named Inventor	Stanka PERC	
SIAI	EMENT :			CANI	Art Unit		
	(Use as many s	neets as n	iecessary)		Examiner Name		
Sheet	2	of	2		Attorney Docket Number	4061-27PUS	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Belda et al., The Tabletting Behaviour of Cellactose® Compared with	
		Mixtures of Celluloses with Lactoses, Eur. J. Pharm. Biopharm. 42(5) 325-330 (1996).	
		Remington: The Science of Practice of Pharmacy, 19 <sup>th</sup> Edition (1995).	
		Encyclopedia of Pharmaceutical Technology: Volume 4, Direct	
		Compression Tableting, British Library	
			_
<del>-, , .</del>			+
			4-
			_

Examiner Signature		Date Considere	-	,	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to